Program
bivamelagon
Also written as “Bivamelagon” and “LB54640”.
Its studies are mostly in Sexual Infantilism · Obesity, led by 2 companies.
Furthest: phase 2, since Sep 14, 20233 company-led studies, 2 open or runningNext primary completion: Apr 15, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rhythm Pharmaceuticals | 21 open or running | phase 2since Sep 14, 2023 | Sep 14, 2023 | Apr 15, 2028phase 2 · NCT07156578 |
| LG Chem | 11 open or running | phase 2since Sep 11, 2023 | Sep 11, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2023First study: phase 2 study in POMC Deficiency ObesityNew to LG ChemLG Chem · NCT06041841 · 4 planned · France, United Kingdom
- Sep 14, 2023Rhythm Pharmaceuticals's first study: phase 2 study in Sexual InfantilismNew to Rhythm PharmaceuticalsRhythm Pharmaceuticals · NCT06046443 · 28 enrolled · United States, United Kingdom
- Aug 25, 2025Phase 2 study in Sexual InfantilismRhythm Pharmaceuticals · NCT07156578 · 25 planned · United States, United Kingdom
Ahead
- Apr 15, 2028Primary completion: phase 2 study in Sexual InfantilismRhythm Pharmaceuticals · NCT07156578
TargetBeta
MC4R →read by rule
“An orally bioavailable agonist of melanocortin-4 receptor (MC4R), ”NCIt, by rule
Other programs on MC4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| setmelanotiderule | Rhythm Pharmaceuticals | phase 4 | 22 |
| bremelanotiderule | palatin-technologies-inc | phase 4 | 8 |
| mifomelatiderule | endevica-bio | phase 2 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07156578Sexual Infantilism · United States, United Kingdom | 2 | By invitation | Rhythm Pharmaceuticals | Apr 15, 2028 | 25 |
| NCT06046443Sexual Infantilism · United States, United Kingdom | 2 | Completed | Rhythm Pharmaceuticals | Feb 9, 2026 | 28 |
| NCT06041841POMC Deficiency Obesity · France, United Kingdom | 2 | Not yet recruiting | LG Chem | Dec 2024 | 4 |
How it is read
Names in the registry
- “Bivamelagon”, 2 entries
- “LB54640”, 1 entry
Conditions, from the studies’ own filings
- Sexual Infantilism, 2 studies
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.